TY - JOUR
T1 - Molecular testing in stage I–III non-small cell lung cancer
T2 - Approaches and challenges
AU - Aggarwal, Charu
AU - Bubendorf, Lukas
AU - Cooper, Wendy A.
AU - Illei, Peter
AU - Borralho Nunes, Paula
AU - Ong, Boon Hean
AU - Tsao, Ming Sound
AU - Yatabe, Yasushi
AU - Kerr, Keith M.
N1 - Funding Information:
The authors would like to acknowledge Sally Cotterill, PhD, CMPP, and (as contracted) Jean Scott, PhD, of Ashfield MedComms, Macclesfield, UK, an Ashfield Health company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
Publisher Copyright:
© 2021
PY - 2021/12
Y1 - 2021/12
N2 - Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted therapies for advanced disease and concomitant molecular testing to inform clinical decision-making. In contrast, routine molecular testing in stage I–III disease has not been required, where standard of care comprises surgery with or without adjuvant or neoadjuvant chemotherapy, or concurrent chemoradiotherapy for unresectable stage III disease, without the integration of targeted therapy. However, the phase 3 ADAURA trial has recently shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, reduces the risk of disease recurrence by 80% versus placebo in the adjuvant setting for patients with stage IB–IIIA EGFR mutation-positive NSCLC following complete tumor resection with or without adjuvant chemotherapy, according to physician and patient choice. Treatment with adjuvant osimertinib requires selection of patients based on the presence of an EGFR-TKI sensitizing mutation. Other targeted agents are currently being evaluated in the adjuvant and neoadjuvant settings. Approval of at least some of these other agents is highly likely in the coming years, bringing with it in parallel, a requirement for comprehensive molecular testing for stage I–III disease. In this review, we consider the implications of integrating molecular testing into practice when managing patients with stage I–III non-squamous NSCLC. We discuss best practices, approaches and challenges from pathology, surgical and oncology perspectives.
AB - Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted therapies for advanced disease and concomitant molecular testing to inform clinical decision-making. In contrast, routine molecular testing in stage I–III disease has not been required, where standard of care comprises surgery with or without adjuvant or neoadjuvant chemotherapy, or concurrent chemoradiotherapy for unresectable stage III disease, without the integration of targeted therapy. However, the phase 3 ADAURA trial has recently shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, reduces the risk of disease recurrence by 80% versus placebo in the adjuvant setting for patients with stage IB–IIIA EGFR mutation-positive NSCLC following complete tumor resection with or without adjuvant chemotherapy, according to physician and patient choice. Treatment with adjuvant osimertinib requires selection of patients based on the presence of an EGFR-TKI sensitizing mutation. Other targeted agents are currently being evaluated in the adjuvant and neoadjuvant settings. Approval of at least some of these other agents is highly likely in the coming years, bringing with it in parallel, a requirement for comprehensive molecular testing for stage I–III disease. In this review, we consider the implications of integrating molecular testing into practice when managing patients with stage I–III non-squamous NSCLC. We discuss best practices, approaches and challenges from pathology, surgical and oncology perspectives.
KW - Adjuvant therapy
KW - Biomarker
KW - Carcinoma, non-small cell
KW - ErbB receptors
KW - Molecular diagnostic techniques
KW - Molecular targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85118511509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118511509&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2021.09.003
DO - 10.1016/j.lungcan.2021.09.003
M3 - Review article
C2 - 34739853
AN - SCOPUS:85118511509
SN - 0169-5002
VL - 162
SP - 42
EP - 53
JO - Lung Cancer
JF - Lung Cancer
ER -